In addition, ruxolitinib, while inhibiting STAT3 activity, also acts synergistically with lenalidomide to effectively inhibit the growth of ABC-DLBCL cells both in vitro and in xenograft mouse models, providing us with a new therapeutic approach (Lu et al., 2018). Here, STAT3 is linked to diffuse large B-cell lymphoma.